Law & policy

Latest content

Why brand-name pharmaceuticals should look to China’s patent linkage system

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

China has recently introduced a unique patent linkage system, which has opened up fresh opportunities for those brand-name pharmaceutical companies that adapt their IP strategies to it.

18 August 2022

Tips and tricks on how to obtain patent protection for polymorphs

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

Obtaining patent protection for a polymorph in addition to a primary compound patent may be particularly advantageous, especially if filed successively, as the polymorph patent may add extra time to the patent protection for the modification of an approved drug or a clinical candidate.

18 August 2022

What made Colombia an attractive venue for Ericsson in its patent battle with Apple

The Swedish company has been a prolific filer in a country whose judicial processes strongly favour plaintiffs

11 August 2022

IPBC Asia all set for Tokyo this autumn

The Asia-Pacific region’s premier event about the business of IP will take place in the Japanese capital from 31 October to 2 November

10 August 2022

Former Beijing IP Court president investigated by anti-corruption commission

Chi Su is under suspicion of “serious violations of discipline and law”, although there is no detail of the specific charges he may be facing

10 August 2022

Tillis’s 101 bill will rev the US innovation engine once again

Paul Michel, former Chief Judge of the US Court of Appeals for the Federal Circuit, and ex-USPTO Director David Kappos urge Congress to embrace legislation designed to repair patent eligibility law which they believe the US Supreme Court has distorted

06 August 2022

UK publishes SEP outreach responses, but no changes are imminent

Despite the increasing attraction of the London courts, the real FRAND focus in Europe is likely to be on EU action which is promised by the end of the year

05 August 2022

Tillis’s 101 reform bill wins plaudits despite flaws

The Patent Eligibility Restoration Act of 2022 effectively overturns Supreme Court precedent and provides greater clarity on eligibility but some believe it may require further work

03 August 2022

Experts react to USPTO planned revision of section 101 guidance

While most observers welcome a revisit, many believe that only the Supreme Court or Congress can deliver significant levels of certainty on eligibility

02 August 2022

Brexit was my toughest challenge, says outgoing UK IP Office head

In an exclusive interview, Tim Moss talks through the five years he spent leading the agency and provides an update on its current study of SEP/FRAND policy issues

02 August 2022

Unlock unlimited access to all IAM content